R
Robert P. Hasserjian
Researcher at Harvard University
Publications - 343
Citations - 21234
Robert P. Hasserjian is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 53, co-authored 284 publications receiving 16118 citations. Previous affiliations of Robert P. Hasserjian include Hammersmith Hospital & Partners HealthCare.
Papers
More filters
Journal ArticleDOI
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Jürgen Thiele,Michael J. Borowitz,Michelle M. Le Beau,Clara D. Bloomfield,Mario Cazzola,James W. Vardiman +8 more
TL;DR: The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.
Journal ArticleDOI
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma,Rafael Bejar,Siddhartha Jaiswal,R. Coleman Lindsley,Mikkael A. Sekeres,Robert P. Hasserjian,Benjamin L. Ebert +6 more
TL;DR: The nature and prevalence of CHIP, distinction of this state from MDS, and current areas of uncertainty regarding diagnostic criteria for myeloid malignancies are discussed.
Journal ArticleDOI
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Marc H.G.P. Raaijmakers,Siddhartha Mukherjee,Shangqin Guo,Siyi Zhang,Tatsuya Kobayashi,Jesse Schoonmaker,Benjamin L. Ebert,Benjamin L. Ebert,Fatima Al-Shahrour,Fatima Al-Shahrour,Robert P. Hasserjian,Edward O. Scadden,Zinmar Aung,Marc Matza,Matthias Merkenschlager,Charles P. Lin,Johanna M. Rommens,David T. Scadden +17 more
TL;DR: It is shown that deletion of Dicer1 specifically in mouse osteoprogenitors, but not in mature osteoblasts, disrupts the integrity of haematopoiesis, and primary stromal dysfunction can result in secondary neoplastic disease, supporting the concept of niche-induced oncogenesis.
Journal ArticleDOI
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.
Warren S. Pear,Jon C. Aster,Martin L. Scott,Robert P. Hasserjian,Benny Soffer,Jeffrey Sklar,David Baltimore +6 more
TL;DR: Results show that TAN1 is an oncoprotein and suggest that truncation and overexpression are important determinants of transforming activity in hematopoietic cells.
Journal ArticleDOI
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Michael Horowitz,Katherine R. Calvo,Hans Michael Kvasnicka,Sa A. Wang,Adam Bagg,Tiziano Barbui,Susan Branford,Carlos E. Bueso-Ramos,Jorge E. Cortes,Paola Dal Cin,Courtney D. DiNardo,Hervé Dombret,Eric J. Duncavage,Benjamin L. Ebert,Elihu H. Estey,Fabio Facchetti,Kathryn Foucar,Naseema Gangat,Umberto Gianelli,Lucy A. Godley,Nicola Goekbuget,Jason Gotlib,Eva Hellström-Lindberg,Gabriela S. Hobbs,Roald Hoffmann,Elias Jabbour,Jean-Jacques Kiladjian,Richard A. Larson,Michelle M. Le Beau,Mignon L. Loh,Bob Löwenberg,Elizabeth Macintyre,Luca Malcovati,Charles G. Mullighan,Charlotte M. Niemeyer,Olatoyosi Odenike,Seishi Ogawa,Alberto Orfao,Elli Papaemmanuil,Francesco Passamonti,Kimmo Porkka,C H Pui,Jerald P. Radich,Andreas Reiter,María Rozman,Martina Rudelius,Michael R. Savona,Charles A. Schiffer,Annette Schmitt-Graeff,Akiko Shimamura,Jorge Sierra,Wendy Stock,Richard Stone,Martin S. Tallman,Juergen Thiele,Hwei-Fang Tien,Alexandar Tzankov,Alessandro M. Vannucchi,Paresh Vyas,Andrew H. Wei,Olga Weinberg,Agnieszka Wierzbowska,Mario Cazzola,Hartmut Döhner,Ayalew Tefferi +67 more
TL;DR: The authors, a group with expertise in the clinical, pathologic and genetic aspects of these disorders, developed the International Consensus Classification (ICC), aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.